open access publication

Note, 2024

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations

Translational Lung Cancer Research, ISSN 2218-6751, Volume 13, 4, Pages 940-946, 10.21037/tlcr-24-98

Contributors

Jorgensen J.T. 0000-0001-6255-0006 (Corresponding author) [1] Urbanska E.M. 0000-0002-4578-9346 [2] Mollerup J. 0000-0001-5455-6061 [3]

Affiliations

  1. [1] Dx-Rx Institute
    2. [NORA names: Miscellaneous; Denmark; Europe, EU; Nordic; OECD];
  2. [2] Rigshospitalet
    3. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [3] Agilent Technologies Denmark Aps
    4. [NORA names: Other Companies; Private Research; Denmark; Europe, EU; Nordic; OECD]

Keywords

MET exon 14-skipping mutations (METex14), Non-small-cell lung cancer (NSCLC), capmatinib, companion diagnostics, tepotinib

Data Provider: Elsevier

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+